<DOC>
	<DOC>NCT01418339</DOC>
	<brief_summary>The goal of the current trial is to determine efficacy and safety of Once-weekly aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.</brief_summary>
	<brief_title>Efficacy &amp; Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>7 to 17 year old with DSMIVTR diagnostic criteria for TD, confirmed by the KSADSPL, including the Diagnostic Supplement 5 Has a TTS â‰¥ 20 on the YGTSS at Screening and Baseline Presenting tic symptoms cause impairment in the subject's normal routines, which include academic achievement, occupational functioning, social activities, and/or relationships Females of childbearing potential must have a negative pregnancy test, must be practicing acceptable doublebarrier methods of contraception and must not be pregnant or lactating. Written ICF obtained from a legally acceptable representative &amp; informed assent at Screening as applicable by trial center's IRB/IEC The subject, designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator. Clinical presentation and/or history, consistent with another neurologic condition that may have accompanying abnormal movements. History of schizophrenia, bipolar disorder, or other psychotic disorder. Subject receiving psychostimulants for treatment of ADD/ADHD and who have developed and/or had exacerbations of tic disorder after initiation of stimulant treatment. Currently meets DSMIVTR criteria for a primary mood disorder. Severe OCD, per CYBOCS score &gt; 16. Taken aripiprazole within 30 days of the Screening visit. Received any investigational agent in a clinical trial within 30 days prior to Screening or who were randomized into a clinical trial with Onceweekly aripiprazole at any time. History of neuroleptic malignant syndrome. Sexually active patients not using 2 approved methods of contraception; breastfeeding or pregnant. Risk of committing suicide Body weight lower than 16 kg Taken neuroleptic or antiparkinson drugs &lt; 14 days prior to randomization. Requiring CBT for TD during trial. Subject meets DSMIVTR criteria for any significant psychoactive substance use disorder within the past 3 months. Positive drug screen Subject requires medications not allowed per protocol Use of CYP2D6 and CYP3A4 inhibitors or CYP3A4 inducers within 14 days prior to dosing and for duration of trial Inability to swallow tablets or tolerate oral medication Abnormal laboratory test results, vital signs and ECG results</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Tourette's Disorder</keyword>
	<keyword>tic disorders</keyword>
</DOC>